Skip to Content

Ledipasvir and Sofosbuvir

Class: HCV Replication Complex Inhibitors
Chemical Name: N-[(1S)-1-[[(6S)-6-[5-[9,9-di fluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic acid methyl ester
Molecular Formula: C49H54F2N8O6C22H29FN3O9P
CAS Number: 1256388-51-8
Brands: Harvoni

Medically reviewed by Drugs.com. Last updated on Jun 22, 2020.

Warning

    Risk of HBV Reactivation in Patients Coinfected with HCV and HBV
  • HBV reactivation, including cases resulting in fulminant hepatitis, hepatic failure, and death, reported in patients coinfected with HCV and HBV who were receiving or had completed treatment with HCV direct-acting antivirals (DAAs) and were not receiving HBV antiviral therapy.1 25 (See Risk of HBV Reactivation in Patients Coinfected with HCV and HBV under Cautions.)

  • Test all patients for evidence of current or prior HBV infection before initiating fixed combination of ledipasvir and sofosbuvir (ledipasvir/sofosbuvir).1 25

  • Monitor patients coinfected with HCV and HBV for hepatitis flare or HBV reactivation during and after HCV treatment.1 25 Initiate appropriate management for HBV infection as clinically indicated.1

Introduction

Antiviral;1 fixed combination containing ledipasvir (HCV NS5A replication complex inhibitor [NS5A inhibitor])1 5 6 and sofosbuvir (nucleotide analog HCV NS5B polymerase inhibitor).1

Uses for Ledipasvir and Sofosbuvir

Chronic HCV Infection

Treatment of chronic HCV genotype 1 infection in treatment-naive (have not previously received HCV treatment) or previously treated adults and pediatric patients ≥3 years of age without cirrhosis or with compensated or decompensated cirrhosis (Child-Pugh class A, B, or C), including those with HIV coinfection and liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 2 3 4 9 29 30 31

Treatment of chronic HCV genotype 4 infection in treatment-naive or previously treated adults and pediatric patients ≥3 years of age without cirrhosis or with compensated cirrhosis (Child-Pugh class A), including those with HIV coinfection and liver transplant recipients.1 12 29 30

Treatment of chronic HCV genotype 5 or 6 infection in treatment-naive or previously treated adults and pediatric patients ≥3 years of age without cirrhosis or with compensated cirrhosis (Child-Pugh class A), including those with HIV coinfection.1 10

Used alone for treatment of chronic HCV infection in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A);1 used in conjunction with ribavirin in those with decompensated cirrhosis (Child-Pugh class B or C) and in liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1

Treatment of chronic HCV infection is complex and rapidly evolving; consult a specialist to obtain the most up-to-date information.119 Information from the American Association for the Study of Liver Diseases (AASLD) and IDSA regarding diagnosis and management of HCV infection, including recommendations for initial treatment, is available at [Web].119

Ledipasvir and Sofosbuvir Dosage and Administration

General

  • For treatment of chronic HCV infection, ledipasvir/sofosbuvir is used alone or in conjunction with ribavirin.1

  • Specific regimen and duration of treatment depend on HCV genotype and certain patient factors (e.g., presence of compensated or decompensated cirrhosis, liver transplantation).1 Consider that relapse rates following treatment are affected by baseline host and viral factors and differ between treatment durations for certain subgroups.1

  • Prior to initiating HCV treatment, test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc).1 25 119 (See Risk of HBV Reactivation in Patients Coinfected with HCV and HBV under Cautions.)

  • Prior to and during treatment, perform appropriate laboratory tests to evaluate liver function, especially in patients with decompensated cirrhosis receiving a regimen of ledipasvir/sofosbuvir in conjunction with ribavirin.1 (See Hepatic Impairment under Cautions.)

Administration

Oral Administration

Administer orally once daily with or without food.1

Available as film-coated tablets and pellets for oral administration;1 use the pellets in pediatric patients who cannot swallow tablets.1

Ledipasvir/sofosbuvir pellets taken with food: Add one or more spoonfuls of nonacidic soft food at or below room temperature (e.g., pudding, chocolate syrup, mashed potato, ice cream) to a bowl; sprinkle entire contents of the appropriate number of single-dose packets of pellets (see Table 1) onto the food and gently mix with a spoon.1 Ensure that no pellets remain in the packet(s).1 Ingest entire mixture containing the pellets within 30 minutes after preparation;1 swallow pellets in the mixture whole without chewing to avoid a bitter aftertaste.1

Ledipasvir/sofosbuvir pellets taken without food: Pour entire contents of single-dose packet of pellets directly into the mouth and swallow pellets whole without chewing to avoid a bitter aftertaste.1 May drink water after swallowing the pellets, if needed.1 If 2 packets of pellets are indicated (see Table 1), repeat the process.1 Ensure that no pellets remain in the packet(s).1

Dosage

Available as fixed-combination pellets containing 33.75 mg of ledipasvir and 150 mg of sofosbuvir, fixed-combination pellets containing 45 mg of ledipasvir and 200 mg of sofosbuvir, fixed-combination tablets containing 45 mg of ledipasvir and 200 mg of sofosbuvir, and fixed-combination tablets containing 90 mg of ledipasvir and 400 mg of sofosbuvir.1

Pediatric Patients

Treatment of Chronic HCV Infection
HCV Genotype 1 Infection
Oral

Treatment-naive or previously treated pediatric patients ≥3 years of age: Dosage based on weight.1 (See Table 1.)

Use alone in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A);1 use with ribavirin in those with decompensated cirrhosis (Child-Pugh class B or C) and in liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 Treatment duration of 12 weeks recommended for most patients;1 treatment duration of 24 weeks recommended in previously treated patients with compensated cirrhosis (Child-Pugh class A).1 (See Table 2.)

Table 1. Recommended Ledipasvir/Sofosbuvir Dosage for Treatment of HCV Genotype 1, 4, 5, or 6 Infection in Pediatric Patients ≥3 Years of Age.1

Weight (kg)

Dosage of Ledipasvir/Sofosbuvir Tablets or Oral Pellets

Total Daily Ledipasvir/Sofosbuvir Dosage

<17

One packet of pellets containing ledipasvir 33.75 mg/sofosbuvir 150 mg once daily

Ledipasvir 33.75 mg/sofosbuvir 150 mg daily

17 to <35

One tablet containing ledipasvir 45 mg/sofosbuvir 200 mg once daily

Ledipasvir 45 mg/sofosbuvir 200 mg daily

or

One packet of pellets containing ledipasvir 45 mg/sofosbuvir 200 mg once daily

≥35

One tablet containing ledipasvir 90 mg/sofosbuvir 400 mg once daily

Ledipasvir 90 mg/sofosbuvir 400 mg daily

or

Two tablets containing ledipasvir 45 mg/sofosbuvir 200 mg once daily

or

Two packets of pellets containing ledipasvir 45 mg/sofosbuvir 200 mg once daily

Manufacturer states treatment duration of 8 weeks can be considered in treatment-naive patients without cirrhosis who have pretreatment HCV RNA levels less than 6 million IU/mL.1

Previously treated defined as patients who failed treatment with peginterferon alfa (with or without ribavirin) with or without an HCV protease inhibitor.1

Alternatively, a regimen of ledipasvir/sofosbuvir and ribavirin for a duration of 12 weeks can be considered in previously treated patients with compensated cirrhosis (Child-Pugh class A) who are eligible to receive ribavirin.1

Use weight-based ribavirin dosage in pediatric patients ≥3 years of age (7.5 mg twice daily in those weighing <47 kg; 200 mg in a.m. and 400 mg in p.m. in those 47–49 kg; 400 mg twice daily in those 50–65 kg; 400 mg in a.m. and 600 mg in p.m. in those 66–80 kg; 600 mg twice daily in those >80 kg).1 Give each ribavirin dose with food.1

Table 2. Recommended Treatment Regimen and Duration of Ledipasvir/Sofosbuvir for HCV Genotype 1 Infection in Pediatric Patients ≥3 Years of Age.1

Patient Type

Treatment Regimen

Duration of Treatment

Treatment-naive without cirrhosis

Ledipasvir/sofosbuvir

12 weeks

Treatment-naive with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Previously treated without cirrhosis

Ledipasvir/sofosbuvir

12 weeks

Previously treated with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

24 weeks

Treatment-naive or previously treated with decompensated cirrhosis (Child-Pugh class B or C)

Ledipasvir/sofosbuvir and ribavirin

12 weeks

Treatment-naive or previously treated liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir and ribavirin

12 weeks

HCV Genotype 4 Infection
Oral

Treatment-naive or previously treated pediatric patients ≥3 years of age: Dosage based on weight.1 (See Table 1.)

Use alone in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A);1 use in conjunction with ribavirin in liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 Treatment duration is 12 weeks.1 (See Table 3.)

Previously treated defined as patients who failed treatment with peginterferon alfa (with or without ribavirin) with or without an HCV protease inhibitor.1

Use weight-based ribavirin dosage in pediatric patients ≥3 years of age (7.5 mg twice daily in those weighing <47 kg; 200 mg in a.m. and 400 mg in p.m. in those 47–49 kg; 400 mg twice daily in those 50–65 kg; 400 mg in a.m. and 600 mg in p.m. in those 66–80 kg; 600 mg twice daily in those >80 kg).1 Give each ribavirin dose with food.1

Table 3. Recommended Treatment Regimen and Duration of Ledipasvir/Sofosbuvir for HCV Genotype 4 Infection in Pediatric Patients ≥3 Years of Age.1

Patient Type

Treatment Regimen

Duration of Treatment

Treatment-naive without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Previously treated without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Treatment-naive or previously treated liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir and ribavirin

12 weeks

HCV Genotype 5 or 6 Infection
Oral

Treatment-naive or previously treated pediatric patients ≥3 years of age: Dosage based on weight.1 (See Table 1.)

Use alone in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 Treatment duration is 12 weeks.1 (See Table 4.)

Previously treated defined as patients who failed treatment with peginterferon alfa (with or without ribavirin) with or without an HCV protease inhibitor.1

Table 4. Recommended Treatment Regimen and Duration of Ledipasvir/Sofosbuvir for HCV Genotype 5 or 6 Infection in Pediatric Patients ≥3 Years of Age.1

Patient Type

Treatment Regimen

Duration of Treatment

Treatment-naive without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Previously treated without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

HCV-infected with HIV Coinfection.
Oral

Treatment-naive or previously treated pediatric patients ≥3 years of age with HCV genotype 1, 4, 5, or 6 infection: Use same dosage and same HCV genotype-specific multiple-drug regimen and duration of treatment recommended for HCV-infected patients without HIV coinfection.1

Adults

Treatment of Chronic HCV Infection
HCV Genotype 1 Infection
Oral

Treatment-naive or previously treated adults: 1 tablet containing ledipasvir 90 mg/sofosbuvir 400 mg once daily.1

Use alone in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A);1 use in conjunction with ribavirin in those with decompensated cirrhosis (Child-Pugh class B or C) and in liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 Treatment duration of 12 weeks recommended for most patients;1 treatment duration of 24 weeks recommended in previously treated patients with compensated cirrhosis (Child-Pugh class A).1 (See Table 5.)

Decompensated cirrhosis (Child-Pugh class B or C): Treatment duration of 12 weeks recommended for most patients.1 Some experts recommend treatment duration of 24 weeks in those who cannot receive ribavirin.119 Referral to an expert (ideally at a liver transplant center) recommended.119

Manufacturer states treatment duration of 8 weeks can be considered in treatment-naive patients without cirrhosis who have pretreatment HCV RNA levels <6 million IU/mL.1

Previously treated defined as patients who failed treatment with peginterferon alfa (with or without ribavirin) with or without an HCV protease inhibitor.1

Alternatively, a regimen of ledipasvir/sofosbuvir and ribavirin for a duration of 12 weeks can be considered in previously treated patients with compensated cirrhosis (Child-Pugh class A) who are eligible to receive ribavirin.1

Use weight-based ribavirin dosage in adults without cirrhosis or with compensated cirrhosis (1 g daily for patients weighing <75 kg or 1.2 g daily for those weighing ≥75 kg).1 In adults with decompensated cirrhosis, starting ribavirin dosage is 600 mg daily and can be titrated up to weight-based ribavirin dosage (up to 1 g daily for patients weighing <75 kg or up to 1.2 g daily for those weighing ≥75 kg).1 Give ribavirin daily dosage in 2 divided doses with food.1 If ribavirin starting dosage not well tolerated, reduce dosage as clinically indicated based on hemoglobin concentrations.1

Table 5. Recommended Treatment Regimen and Duration of Ledipasvir/Sofosbuvir for HCV Genotype 1 Infection in Adults.1

Patient Type

Treatment Regimen

Duration of Treatment

Treatment-naive without cirrhosis

Ledipasvir/sofosbuvir

12 weeks

Treatment-naive with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Previously treated without cirrhosis

Ledipasvir/sofosbuvir

12 weeks

Previously treated with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

24 weeks

Treatment-naive or previously treated with decompensated cirrhosis (Child-Pugh class B or C)

Ledipasvir/sofosbuvir and ribavirin

12 weeks

Treatment-naive or previously treated liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir and ribavirin

12 weeks

HCV Genotype 4 Infection
Oral

Treatment-naive or previously treated adults: 1 tablet containing ledipasvir 90 mg/sofosbuvir 400 mg once daily.1

Use alone in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A);1 use in conjunction with ribavirin in liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 Treatment duration is 12 weeks.1 (See Table 6.)

Decompensated cirrhosis (Child-Pugh class B or C): Some experts recommend a 12-week regimen of ledipasvir/sofosbuvir given in a dosage of 1 tablet containing ledipasvir 90 mg/sofosbuvir 400 mg once daily in conjunction with ribavirin.119 If ledipasvir/sofosbuvir (without ribavirin) used in patients with decompensated cirrhosis who cannot receive ribavirin, these experts recommend treatment duration of 24 weeks.119 Referral to an expert (ideally at a liver transplant center) recommended.119

Previously treated defined as patients who failed treatment with peginterferon alfa (with or without ribavirin) with or without an HCV protease inhibitor.1

Use weight-based ribavirin dosage in adults without cirrhosis or with compensated cirrhosis (1 g daily for patients weighing <75 kg or 1.2 g daily for those weighing ≥75 kg).1 In adults with decompensated cirrhosis, starting ribavirin dosage is 600 mg daily and can be titrated up to weight-based ribavirin dosage (up to 1 g daily for patients weighing <75 kg or up to 1.2 g daily for those weighing ≥75 kg).1 Give ribavirin daily dosage in 2 divided doses with food.1 If ribavirin starting dosage not well tolerated, reduce dosage as clinically indicated based on hemoglobin concentrations.1

Table 6. Recommended Treatment Regimen and Duration of Ledipasvir/Sofosbuvir for HCV Genotype 4 Infection in Adults.1

Patient Type

Treatment Regimen

Duration of Treatment

Treatment-naive without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Previously treated without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Treatment naive or previously treated liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir and ribavirin

12 weeks

HCV Genotype 5 or 6 Infection
Oral

Treatment-naive or previously treated adults: 1 tablet containing ledipasvir 90 mg/sofosbuvir 400 mg once daily.1

Use alone in patients without cirrhosis or with compensated cirrhosis (Child-Pugh class A).1 Treatment duration is 12 weeks.1 (See Table 7.)

Decompensated cirrhosis (Child-Pugh class B or C): Some experts recommend a 12-week regimen of ledipasvir/sofosbuvir given in a dosage of 1 tablet containing ledipasvir 90 mg/sofosbuvir 400 mg once daily in conjunction with ribavirin.119 If ledipasvir/sofosbuvir (without ribavirin) used in patients with decompensated cirrhosis who cannot receive ribavirin, these experts recommend treatment duration of 24 weeks.119 Referral to an expert (ideally at a liver transplant center) recommended.119

Previously treated defined as patients who failed treatment with peginterferon alfa (with or without ribavirin) with or without an HCV protease inhibitor.1

Table 7. Recommended Treatment Regimen and Duration of Ledipasvir/Sofosbuvir for HCV Genotype 5 or 6 Infection in Adults.1

Patient Type

Treatment Regimen

Duration of Treatment

Treatment-naive without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

Previously treated without cirrhosis or with compensated cirrhosis (Child-Pugh class A)

Ledipasvir/sofosbuvir

12 weeks

HCV-infected with HIV Coinfection.
Oral

Treatment-naive or previously treated adults with HCV genotype 1, 4, 5, or 6: Use same dosage and same HCV genotype-specific multiple-drug regimen and duration of treatment recommended for HCV-infected patients without HIV coinfection.1

Special Populations

Hepatic Impairment

Mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, or C): Dosage adjustments not needed.1 (See Hepatic Impairment under Cautions.)

Renal Impairment

Mild, moderate, or severe renal impairment, including end-stage renal disease (ESRD) requiring dialysis: Dosage adjustments not needed.1 (See Renal Impairment under Cautions.)

Geriatric Patients

Dosage adjustments not needed.1

Cautions for Ledipasvir and Sofosbuvir

Contraindications

  • If ledipasvir/sofosbuvir used in conjunction with ribavirin, the contraindications to ribavirin also apply.1 (See Precautions Related to Fixed Combinations and Multiple-drug Treatment Regimens under Cautions.)

Warnings/Precautions

Warnings

Risk of HBV Reactivation in Patients Coinfected with HCV and HBV

Postmarketing reports of reactivation of HBV infection when DAAs were used for treatment of HCV infection in patients with HBV coinfection;1 25 fulminant hepatitis, hepatic failure, and death reported in some cases.1 25

HBV reactivation (abrupt increase in HBV replication manifested as rapid increase in serum HBV DNA levels or detection of HBsAg in an individual who was previously HBsAg negative and anti-HBc positive) reported in patients with HCV and HBV coinfection receiving HCV treatment with a regimen that included HCV DAAs without interferon alfa.1 25 HBV reactivation usually occurred within 4–8 weeks after initiation of HCV treatment.25

Patients with HBV reactivation heterogeneous in terms of HCV genotype and baseline HBV disease.25 Some patients were HBsAg positive; others had serologic evidence of resolved HBV infection (i.e., HBsAg negative and anti-HBc positive).1 25

HBV reactivation also reported in patients receiving certain immunosuppressant or chemotherapeutic drugs;1 risk of reactivation associated with HCV DAAs may be increased in such patients.1

Mechanism for HBV reactivation in coinfected patients receiving HCV DAAs unknown.25 Although HCV DAAs not known to cause immunosuppression, HBV reactivation in coinfected patients may result from a complex interplay of host immunologic responses in the setting of infection with 2 hepatitis viruses.25

Prior to initiating treatment with an HCV DAA, including ledipasvir/sofosbuvir, screen all patients for evidence of current or prior HBV infection by measuring HBsAg, anti-HBs, and anti-HBc.1 25 119 If there is serologic evidence of HBV infection, measure baseline HBV DNA level.25 119

In all patients with evidence of current or prior HBV infection, monitor for clinical and laboratory signs (i.e., HBsAg, HBV DNA levels, serum aminotransferase and bilirubin concentrations) of hepatitis flare or HBV reactivation during and after treatment with HCV DAAs.1 25 119 Initiate appropriate management for HBV infection as clinically indicated.1 119

Advise coinfected patients to immediately contact a clinician if they develop any signs or symptoms of serious liver injury.25 (See Advice to Patients.)

When making decisions regarding HBV monitoring or HBV treatment in coinfected patients, consult a clinician with expertise in managing HBV infection.25 119

Sensitivity Reactions

Angioedema and rash, sometimes with blisters or angioedema-like swelling, reported during postmarketing experience.1

Other Warnings/Precautions

Cardiovascular Effects

Postmarketing reports of symptomatic bradycardia, including cases requiring pacemaker intervention, in patients receiving amiodarone concomitantly with ledipasvir/sofosbuvir.1 23 Fatal cardiac arrest reported in one patient.1

In most reported cases, bradycardia occurred within hours to days after HCV treatment initiated in patients receiving amiodarone (also has been observed up to 2 weeks after initiation of HCV treatment) and resolved after HCV treatment discontinued.1 Mechanism for this adverse cardiovascular effect unknown.1

Patients who may be at increased risk for symptomatic bradycardia if amiodarone used concomitantly with ledipasvir/sofosbuvir include those also receiving a β-adrenergic blocking agent, those with underlying cardiac comorbidities, and/or those with advanced liver disease.1

Concomitant use of amiodarone with ledipasvir/sofosbuvir not recommended.1

If there are no alternative HCV treatment options and regimen of ledipasvir/sofosbuvir must be used in a patient receiving amiodarone, advise patient about the risk of serious bradycardia before initiating HCV treatment.1 Perform cardiac monitoring in an inpatient setting during first 48 hours of concomitant use of amiodarone and ledipasvir/sofosbuvir;1 heart rate monitoring should then be performed daily (outpatient or self-monitoring) through at least the first 2 weeks of concomitant use.1 Similar cardiac monitoring recommended in patients who discontinued amiodarone just prior to initiation of ledipasvir/sofosbuvir or if there are no other treatment options and amiodarone must be initiated in a patient already receiving ledipasvir/sofosbuvir.1

Advise patients receiving amiodarone concomitantly with ledipasvir/sofosbuvir to immediately contact a clinician if signs or symptoms of bradycardia (e.g., near-fainting or fainting, dizziness or lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion, memory problems) develop.1

Interactions

Concomitant use of ledipasvir/sofosbuvir and inducers of the P-glycoprotein (P-gp) transport system (e.g., rifampin, St. John's wort) not recommended.1 (See Interactions.)

Precautions Related to Fixed Combinations and Multiple-drug Treatment Regimens

Consider cautions, precautions, contraindications, and drug interactions associated with both drugs in the fixed combination (i.e., ledipasvir, sofosbuvir).1 Consider cautionary information applicable to specific populations (e.g., pregnant or nursing women, individuals with hepatic or renal impairment, geriatric patients) for both drugs.1

When used in conjunction with ribavirin, consider that ribavirin may cause fetal toxicity and/or death.349 Extreme care must be taken to avoid pregnancy in female patients and female partners of male patients receiving a ribavirin-containing regimen.349 Obtain a negative pregnancy test for female patients of childbearing potential immediately prior to initiating ribavirin;349 perform pregnancy tests periodically during and for 6 months after ribavirin treatment is completed.349 Women of childbearing potential (and their male partners) and male patients (and their female partners) must use effective contraception during and for 6 months after ribavirin treatment is completed.349

Specific Populations

Pregnancy

Adequate data regarding use of ledipasvir/sofosbuvir in pregnant women not available.1 In animal studies, neither ledipasvir nor sofosbuvir affected fetal development at dosages tested.1

When used in conjunction with ribavirin, consider that ribavirin is contraindicated in pregnant women and male partners of pregnant women.1 349 (See Precautions Related to Fixed Combinations and Multiple-drug Treatment Regimens under Cautions.)

Lactation

Not known whether ledipasvir, sofosbuvir, or their metabolites distribute into human milk, affect milk production, or affect breast-fed child.1

Predominant metabolite of sofosbuvir (GS-331007) distributed into milk in rats;1 ledipasvir detected in plasma of suckling rat pups.1 No apparent effects on the nursing pups.1

Consider benefits of breast-feeding and importance of the drug to the woman;1 also consider potential adverse effects on the breast-fed child from the drug or underlying maternal condition.1

When used in conjunction with ribavirin,1 consider potential for adverse reactions to ribavirin in nursing infants.349 (See Precautions Related to Fixed Combinations and Multiple-drug Treatment Regimens under Cautions.)

Pediatric Use

Safety and efficacy not established in pediatric patients <3 years of age.1

Safety and efficacy for treatment of HCV genotype 1 or 4 infection in treatment-naive and previously treated pediatric patients ≥3 years of age without cirrhosis or with compensated cirrhosis (Child-Pugh class A) have been established in an open-label clinical study.1

Safety and efficacy for treatment of HCV genotype 1 infection in pediatric patients ≥3 years of age with decompensated cirrhosis (Child-Pugh class B or C) and for treatment of HCV genotype 1 or 4 infection in pediatric patients ≥3 years of age who are liver transplant recipients without cirrhosis or with compensated cirrhosis (Child-Pugh class A) are supported by pharmacokinetic data indicating that ledipasvir, sofosbuvir, and GS-331007 exposures in pediatric patients ≥3 years of age with HCV genotype 1, 3, or 4 infection are similar to exposures in adults.1

Safety and efficacy for treatment of HCV genotype 5 or 6 infection in pediatric patients ≥3 years of age are supported by pharmacokinetic data indicating that ledipasvir, sofosbuvir, and GS-331007 exposures in pediatric patients ≥3 years of age with HCV genotype 1, 3, or 4 infection are similar to exposures in adults.1

Adverse effects in pediatric patients ≥3 years of age are similar to those observed in adults.1

Data not available regarding safety and pharmacokinetics in pediatric patients with renal impairment.1

Geriatric Use

No overall differences in safety and efficacy in patients ≥65 years of age compared with younger adults,1 but increased sensitivity in some older individuals cannot be ruled out.1

Hepatic Impairment

Severe hepatic impairment (Child-Pugh class C) without HCV infection: Ledipasvir exposure similar to exposure in individuals with normal hepatic function.1

HCV-infected individuals with moderate or severe hepatic impairment (Child-Pugh class B or C): Increased sofosbuvir and GS-331007 exposures compared with exposures in individuals with normal hepatic function.1

When ledipasvir/sofosbuvir is used in conjunction with ribavirin in patients with decompensated cirrhosis (Child-Pugh class B or C), clinical and hepatic laboratory monitoring recommended as clinically indicated.1

Data not available regarding safety of ledipasvir/sofosbuvir in patients with decompensated cirrhosis and severe renal impairment, including those requiring dialysis.1

Renal Impairment

Severe renal impairment without HCV infection: Ledipasvir exposure similar to exposure in healthy individuals;1 substantially increased sofosbuvir and GS-331007 exposures compared with exposures in individuals with normal renal function.1

Severe renal impairment or end-stage renal disease (ESRD) requiring hemodialysis without HCV infection: Sofosbuvir and GS-331007 plasma exposures substantially higher compared with exposures in individuals with normal renal function.1

Data not available regarding safety of ledipasvir/sofosbuvir in patients with severe renal impairment, including those requiring dialysis, who also have decompensated cirrhosis.1

HCV-infected with HIV Coinfection

Safety profile of ledipasvir/sofosbuvir in individuals with HCV genotype 1 or 4 infection and HIV-1 coinfection generally comparable to that reported in HCV-infected individuals without HIV-1 coinfection.1

Common Adverse Effects

Ledipasvir/sofosbuvir: Fatigue,1 2 3 4 9 10 headache,1 2 3 4 9 10 nausea,1 2 3 4 9 diarrhea,1 2 3 4 9 10 abdominal pain,10 insomnia or sleep disorder,1 2 3 4 9 irritability,1 2 9 rash,2 4 pruritus,2 dry skin,9 arthralgia,3 4 9 10 myalgia,1 9 10 back pain,9 asthenia,2 9 10 cough,1 2 4 9 10 upper respiratory tract infection,4 9 10 dizziness.1 4 10

Ledipasvir/sofosbuvir in conjunction with ribavirin: Fatigue,9 headache,1 9 nausea,9 diarrhea,9 insomnia,9 asthenia,1 9 cough,1 9 bronchitis,9 dyspnea,1 irritability,1 9 pruritus,9 dry skin,9 myalgia,9 decreased hemoglobin.1

Interactions for Ledipasvir and Sofosbuvir

Ledipasvir inhibits P-gp transport system.1 Ledipasvir and sofosbuvir are substrates of P-gp.1

Ledipasvir inhibits breast cancer resistance protein (BCRP).1 Ledipasvir and sofosbuvir are substrates of BCRP.1

At concentrations exceeding those achieved in clinical settings, ledipasvir inhibits organic anion transporting polypeptide (OATP) 1B1, OATP1B3, and the bile salt export pump (BSEP).1

The following drug interactions are based on studies using ledipasvir/sofosbuvir, ledipasvir alone, or sofosbuvir alone.1 When ledipasvir/sofosbuvir used, consider interactions associated with both drugs in the fixed combination.1

Drugs Affecting or Affected by P-glycoprotein Transport System

P-gp substrates: Concomitant use of ledipasvir and P-gp substrates may increase intestinal absorption of such drugs.1

P-gp inducers: Possible decreased ledipasvir and sofosbuvir plasma concentrations leading to reduced therapeutic effect.1 Concomitant use not recommended.1

Drugs Affecting or Affected by Breast Cancer Resistance Protein

BCRP substrates: Concomitant use of ledipasvir and BCRP substrates may increase intestinal absorption of such drugs.1

Inhibitors of BCRP: Possible increased plasma concentrations of ledipasvir and sofosbuvir without increase in plasma concentrations of GS-331007.1

Specific Drugs

Drug

Interaction

Comments

Abacavir

Abacavir: Clinically important pharmacokinetic interactions not expected1

Fixed combination of abacavir and lamivudine (abacavir/lamivudine): No clinically important effects on pharmacokinetics of abacavir, lamivudine, ledipasvir, or sofosbuvir8

Antacids (aluminum, magnesium hydroxide)

Decreased ledipasvir concentrations expected;1 increased gastric pH decreases ledipasvir solubility1

Take antacids 4 hours before or after ledipasvir/sofosbuvir1

Antiarrhythmic agents (amiodarone)

Amiodarone: Concomitant use with ledipasvir/sofosbuvir may result in serious symptomatic bradycardia1 23 (mechanism unknown);1 effect on amiodarone, ledipasvir, and sofosbuvir concentrations unknown1

Amiodarone: Concomitant use with ledipasvir/sofosbuvir not recommended;1 if concomitant use required, patient counseling and cardiac monitoring required1 (see Cardiovascular Effects under Cautions)

Anticonvulsants (carbamazepine, phenytoin, phenobarbital)

Carbamazepine: Decreased sofosbuvir concentrations and AUC1

Phenytoin, phenobarbital: Decreased ledipasvir and sofosbuvir concentrations expected;1 may lead to reduced therapeutic effect1

Carbamazepine, phenytoin, phenobarbital: Concomitant use with ledipasvir/sofosbuvir not recommended1

Antidiabetic agents

Altered blood glucose control resulting in serious symptomatic hypoglycemia reported when HCV DAAs used in diabetic patients receiving antidiabetic agents1

Frequently monitor glucose concentrations;1 may need to adjust antidiabetic agent dosage1

Antimycobacterial agents (rifabutin, rifampin, rifapentine)

Rifabutin: Decreased sofosbuvir concentrations and AUC;1 decreased ledipasvir concentrations expected1

Rifampin, rifapentine: Decreased ledipasvir and sofosbuvir concentrations expected;1 may lead to reduced therapeutic effect1

Rifabutin, rifampin, rifapentine: Concomitant use with ledipasvir/sofosbuvir not recommended1

Atazanavir

Ritonavir-boosted atazanavir: Increased atazanavir and ledipasvir AUCs; no clinically important effects on pharmacokinetics of sofosbuvir1 200

Cobicistat-boosted or unboosted atazanavir: Clinically important pharmacokinetic interactions not expected200

HIV antiretroviral regimens that include ritonavir-boosted or cobicistat-boosted atazanavir and tenofovir disoproxil fumarate (TDF): Possible increased tenofovir concentrations if used with ledipasvir/sofosbuvir;1 200 221 safety of increased tenofovir concentrations not established1 221

Ritonavir-boosted, cobicistat-boosted, or unboosted atazanavir: Dosage adjustments not needed200

HIV antiretroviral regimens that include ritonavir-boosted or cobicistat-boosted atazanavir and TDF: Consider alternative HCV treatment or alternative antiretroviral therapy;1 221 if concomitant use with ledipasvir/sofosbuvir necessary, monitor for tenofovir-associated adverse effects1 200 221

Bictegravir

Fixed combination of bictegravir, emtricitabine, and tenofovir alafenamide fumarate (bictegravir/emtricitabine/TAF): No clinically important pharmacokinetic interactions with ledipasvir/sofosbuvir248

Darunavir

Ritonavir-boosted darunavir: No clinically important effects on pharmacokinetics of darunavir, ritonavir, ledipasvir, or sofosbuvir1 200

Cobicistat-boosted darunavir: Clinically important pharmacokinetic interactions not expected200

HIV antiretroviral regimens that include ritonavir-boosted or cobicistat-boosted darunavir and TDF: Possible increased tenofovir concentrations if used with ledipasvir/sofosbuvir;1 200 221 safety of increased tenofovir concentrations not established1 200 221

Ritonavir-boosted or cobicistat-boosted darunavir: Dosage adjustments not needed200

HIV antiretroviral regimens that include ritonavir-boosted or cobicistat-boosted darunavir and TDF: Consider alternative HCV treatment or alternative antiretroviral therapy;1 221 if concomitant use with ledipasvir/sofosbuvir necessary, monitor for tenofovir-associated adverse effects1 200 221

Digoxin

Possible increased digoxin concentrations1

Digoxin therapeutic concentration monitoring recommended1

Dolutegravir

Clinically important pharmacokinetic interactions not expected1 200

Dolutegravir: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimens that include dolutegravir and TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

Doravirine

Doravirine: No clinically important pharmacokinetic interactions with ledipasvir/sofosbuvir200

Fixed combination of doravirine, lamivudine, and TDF (doravirine/lamivudine/TDF): Increased tenofovir concentrations if used with ledipasvir/sofosbuvir254

Doravirine: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

Doravirine/lamivudine/TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir254

Efavirenz

Efavirenz: Possible decreased ledipasvir concentrations and AUC;200 no clinically important effects on sofosbuvir or efavirenz pharmacokinetics1 200

Fixed combination of efavirenz, emtricitabine, and TDF (efavirenz/emtricitabine/TDF): Decreased ledipasvir concentrations and AUC;1 no clinically important effects on pharmacokinetics of efavirenz or sofosbuvir1

Efavirenz: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimen that includes efavirenz and TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

Elvitegravir

Cobicistat-boosted elvitegravir: Increased concentrations and AUC of ledipasvir and cobicistat;8 no clinically important effects on pharmacokinetics of elvitegravir or sofosbuvir8

Fixed combination of elvitegravir, cobicistat, emtricitabine, and TAF (EVG/c/FTC/TAF): No clinically important effects on any of the drugs1

Fixed combination of elvitegravir, cobicistat, emtricitabine, and TDF (EVG/c/FTC/TDF): Increased ledipasvir and tenofovir concentrations;1 200 safety of increased tenofovir concentrations not established1

EVG/c/FTC/TAF: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

EVG/c/FTC/TDF: Concomitant use with ledipasvir/sofosbuvir not recommended1 200

Emtricitabine

Clinically important pharmacokinetic interactions not expected1

Estrogens and progestins

Oral contraceptive containing ethinyl estradiol and norgestimate: No clinically important effects on pharmacokinetics of ethinyl estradiol or norgestimate and its active metabolites (norelgestromin, norgestrel) when used concomitantly with ledipasvir or sofosbuvir;1 7 efficacy of the oral contraceptive not expected to be affected7

Etravirine

Clinically important pharmacokinetic interactions not expected200

Etravirine: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimens that include etravirine and TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

Histamine H2-receptor antagonists

Decreased ledipasvir concentrations expected;1 increased gastric pH decreases ledipasvir solubility1

Administer H2-antagonists concomitantly with or 12 hours apart from ledipasvir/sofosbuvir;1 do not exceed H2-antagonist dosages comparable to famotidine 40 mg twice daily1

HMG-CoA reductase inhibitors (statins)

Atorvastatin: Possible increased atorvastatin concentrations and increased risk of myopathy and rhabdomyolysis1

Pravastatin: Clinically important interactions not expected1

Rosuvastatin: Possible increased rosuvastatin concentrations and increased risk of myopathy and rhabdomyolysis1

Atorvastatin: Monitor closely for adverse effects, including myopathy and rhabdomyolysis1

Rosuvastatin: Concomitant use with ledipasvir/sofosbuvir not recommended1

Immunosuppressive agents (cyclosporine, tacrolimus)

Cyclosporine: Pharmacokinetics of cyclosporine not affected by ledipasvir or sofosbuvir;1 clinically important interactions not expected if used with ledipasvir/sofosbuvir1

Tacrolimus: Clinically important interactions not expected1

Lamivudine

Lamivudine: Clinically important pharmacokinetic interactions not expected1

Abacavir/lamivudine: No clinically important effects on pharmacokinetics of abacavir, lamivudine, ledipasvir, or sofosbuvir8

Lopinavir

HIV antiretroviral regimens that include fixed combination of lopinavir and ritonavir (lopinavir/ritonavir) and TDF: Possible increased tenofovir concentrations if used concomitantly with ledipasvir/sofosbuvir;1 200 safety of increased tenofovir concentrations not established1

HIV antiretroviral regimens that include lopinavir/ritonavir and TDF: Consider alternative HCV treatment or alternative antiretroviral therapy;1 200 if concomitant use with ledipasvir/sofosbuvir necessary, monitor for tenofovir-associated adverse effects1 200

Maraviroc

Clinically important effect on maraviroc pharmacokinetics not expected200

Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

Methadone

Methadone pharmacokinetics not affected by ledipasvir or sofosbuvir;1 clinically important interactions not expected if used with ledipasvir/sofosbuvir1

Midazolam

Ledipasvir has no clinically important effects on midazolam pharmacokinetics

Nevirapine

Clinically important pharmacokinetic interactions not expected200

Nevirapine: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimens that include nevirapine and TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

Proton-pump inhibitors

Decreased ledipasvir concentrations expected;1 increased gastric pH decreases ledipasvir solubility1

Administer proton-pump inhibitors concomitantly with ledipasvir/sofosbuvir under fasting conditions;1 do not exceed proton-pump inhibitor dosages comparable to 20 mg of omeprazole once daily1

Raltegravir

No clinically important effects on pharmacokinetics of raltegravir, ledipasvir, or sofosbuvir1

Raltegravir: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimens that include raltegravir and TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir1 200

Rilpivirine

Rilpivirine: No clinically important effects on pharmacokinetics of rilpivirine, ledipasvir, or sofosbuvir1

Rilpivirine: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimens that include rilpivirine and TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

Saquinavir

HIV antiretroviral regimens that include ritonavir-boosted saquinavir and TDF: Possible increased tenofovir concentrations if used with ledipasvir/sofosbuvir;200 safety of increased tenofovir concentrations not established1

HIV antiretroviral regimens that include ritonavir-boosted saquinavir and TDF: Consider alternative HCV treatment or alternative antiretroviral therapy;1 if concomitant use with ledipasvir/sofosbuvir necessary, monitor for tenofovir-associated adverse effects200

St. John's wort (Hypericum perforatum)

Decreased ledipasvir and sofosbuvir concentrations;1 may result in loss of therapeutic effect of ledipasvir/sofosbuvir1

Concomitant use with ledipasvir/sofosbuvir not recommended1

Tenofovir

Tenofovir alafenamide fumarate (TAF): Increased tenofovir concentrations if used with ledipasvir/sofosbuvir;200 not considered clinically important246

Tenofovir disoproxil fumarate (TDF): Increased tenofovir concentrations and AUC if used with ledipasvir/sofosbuvir1 221

HIV antiretroviral regimens that include TDF and a ritonavir-boosted or cobicistat-boosted HIV protease inhibitor (PI): Increased tenofovir concentrations expected if used with ledipasvir/sofosbuvir;1 200 safety of increased tenofovir concentrations in this setting not established1 200 221

HIV antiretroviral regimens that include TDF and an HIV integrase inhibitor (INSTI): Possible increased tenofovir concentrations200

HIV antiretroviral regimens that include TDF and an HIV nonnucleoside reverse transcriptase inhibitor (NNRTI): Possible increased tenofovir concentrations200

TAF: Dosage adjustments not needed if used with ledipasvir/sofosbuvir200

TDF: Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir1 200 221

HIV antiretroviral regimens that include TDF and a ritonavir-boosted or cobicistat-boosted HIV PI: Consider alternative HCV treatment or alternative antiretroviral therapy;1 200 221 if concomitant use with ledipasvir/sofosbuvir necessary, monitor for tenofovir-associated adverse effects1 200 221

HIV antiretroviral regimens that include TDF and an HIV INSTI (e.g., dolutegravir, elvitegravir, raltegravir): Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

HIV antiretroviral regimens that include TDF and an HIV NNRTI (e.g., doravirine, efavirenz, etravirine, nevirapine, rilpivirine): Monitor for tenofovir-associated adverse effects if used with ledipasvir/sofosbuvir200

Tipranavir

Ritonavir-boosted tipranavir: Decreased concentrations of ledipasvir and sofosbuvir expected;1 may lead to reduced therapeutic effect of ledipasvir/sofosbuvir1

Ritonavir-boosted tipranavir: Concomitant use with ledipasvir/sofosbuvir not recommended1 200

Verapamil

Clinically important interactions not expected1

Warfarin

Subtherapeutic INR reported after initiation of sofosbuvir-containing regimens in patients receiving warfarin26 27 28

Closely monitor INR,1 26 27 28 especially when initiating or discontinuing ledipasvir/sofosbuvir;26 27 28 may need to adjust warfarin dosage1

Ledipasvir and Sofosbuvir Pharmacokinetics

Absorption

Bioavailability

Following oral administration of ledipasvir/sofosbuvir in adults, peak plasma concentrations of ledipasvir occur approximately 4–4.5 hours after a dose.1 Peak plasma concentrations and AUC of ledipasvir are 32 and 24% lower, respectively, in HCV-infected adults compared with healthy adults.1

Following oral administration of ledipasvir/sofosbuvir in adults, peak plasma concentrations of sofosbuvir and predominant sofosbuvir metabolite (GS-331007) occur approximately 0.8–1 and 3.5–4 hours, respectively, after a dose;1 GS-331007 accounts for >90% of total systemic exposure.1 Peak plasma concentrations and AUC of sofosbuvir and GS-331007 are similar in HCV-infected and healthy adults.1

Food

Administration of ledipasvir/sofosbuvir with moderate-fat (approximately 600 kcal, 25–30% fat) or high-fat (approximately 1000 kcal, 50% fat) meal does not substantially affect ledipasvir or GS-331007 exposures relative to administration in fasting state;1 sofosbuvir peak plasma concentrations not affected, but AUC is increased approximately twofold.1

Special Populations

Ledipasvir: In individuals with severe hepatic impairment (Child-Pugh class C) without HCV infection, AUC of ledipasvir after single 90-mg dose is similar to that observed in individuals with normal hepatic function.1

Sofosbuvir: In HCV-infected individuals with moderate or severe hepatic impairment (Child-Pugh class B or C), sofosbuvir AUC is 126 or 143% higher, respectively, compared with individuals with normal hepatic function;1 GS-331007 AUC is 18 or 9% higher, respectively.1

Ledipasvir: In individuals with severe renal impairment without HCV infection, no clinically important differences in ledipasvir pharmacokinetics after single 90-mg dose compared with healthy individuals.1

Sofosbuvir: In individuals with mild, moderate, or severe renal impairment without HCV infection, sofosbuvir AUC after single 400-mg dose is 61, 107, or 171% higher, respectively, compared with individuals with normal renal function;1 GS-331007 AUC is 55, 88, or 451% higher, respectively.1

Population pharmacokinetic analysis in HCV-infected individuals indicates cirrhosis does not substantially affect ledipasvir, sofosbuvir, or GS-331007 exposures.1

Population pharmacokinetic analysis in HCV-infected individuals indicates peak plasma concentrations and AUC of ledipasvir are 58 and 77% higher, respectively, in females than in males;1 not considered clinically important.1 Gender did not affect sofosbuvir or GS-331007 exposures.1

Population pharmacokinetic analysis indicates that age (range 18–80 years) and race do not have clinically important effects on ledipasvir, sofosbuvir, or GS-331007 exposures.1

Pediatric patients ≥3 years of age with HCV genotype 1, 3, or 4 infection: Pharmacokinetics of ledipasvir, sofosbuvir, and GS-331007 comparable to those in adults.1 Pharmacokinetics not established in pediatric patients <3 years of age.1

Distribution

Plasma Protein Binding

Ledipasvir: >99.8%.1

Sofosbuvir: Approximately 61–65%;1 GS-331007 has minimal protein binding.1

Elimination

Metabolism

Ledipasvir: Slow oxidative metabolism occurs by unknown mechanism;1 systemic exposure is almost exclusively the parent drug.1

Sofosbuvir: Prodrug that undergoes intracellular metabolic activation in the liver (hydrolysis by human cathepsin A [CatA] or carboxylesterase 1 [CES1], phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 [HINT1], and phosphorylation by pyrimidine nucleotide biosynthesis pathway).1 Results in formation of pharmacologically active metabolite, GS-461203.1 Desphosphorylation subsequently occurs leading to formation of GS-331007 (the predominant circulating metabolite);1 GS-331007 has no anti-HCV activity.1

Elimination Route

Ledipasvir: Major route of elimination is biliary excretion.1 Following single 90-mg oral dose, 86% excreted in feces (70% as unchanged ledipasvir, 2.2% as the oxidative metabolite);1 1% excreted in urine.1

Sofosbuvir: Major route of elimination is renal clearance.1 Following single 400-mg oral dose, 80% eliminated in urine (mainly as GS-331007), 14% excreted in feces, and 2.5% in expired air.1

Half-life

Ledipasvir: 47 hours.1

Sofosbuvir: 0.5 hours;1 GS-331007 has half-life of 27 hours.1

Special Populations

Ledipasvir: Removal by hemodialysis unlikely since highly bound to plasma protein.1

Sofosbuvir: Hemodialysis (4-hour session) removes approximately 18% of dose.1

Stability

Storage

Oral

Film-coated Tablets

Room temperature <30ºC.1

Dispense only in original container.1

Pellets

Single-use packets: Room temperature <30ºC.1

After mixing with soft food, use within 30 minutes; do not store or use any leftover mixture.1 (See Administration under Dosage and Administration.)

Actions and Spectrum

  • Ledipasvir/sofosbuvir is a fixed combination of 2 HCV antivirals.1 Ledipasvir is an HCV NS5A replication complex inhibitor (NS5A inhibitor)1 5 6 and sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor.1

  • Ledipasvir and sofosbuvir are both direct-acting antivirals (DAAs) with activity against HCV.1 No in vitro evidence of antagonistic anti-HCV effects between the drugs in HCV replicon studies.1

  • Ledipasvir targets HCV NS5A protein, which is required for viral replication.1 In vitro studies using cell-based replicon assays indicate ledipasvir has activity against HCV genotypes 1a and 1b.1 5 6 Also has some antiviral activity against HCV genotypes 4a, 5a, and 6a, but substantially lower activity against HCV genotype 6e.1

  • Sofosbuvir is a prodrug that undergoes metabolic activation in the liver to a pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by NS5B polymerase;1 acts as RNA chain terminator.1 In vitro studies using biochemical and cell-based replicon assays indicate GS-461203 has activity against HCV genotypes 1a, 1b, 4a, 5a, and 6a.1

  • Certain amino acid substitutions in NS5A of HCV genotype 1a (e.g., Y93H, Q30E) and genotype 1b (e.g., Y93H) have been selected in cell culture and have been associated with reduced susceptibility to ledipasvir in vitro in replicon studies.1 6 Treatment-emergent NS5A ledipasvir resistance-associated substitutions, including K24R, M28T/V, Q30R/H/K/L, L31M/V, H58D/P, and/or Y93H/N/C in HCV genotype 1a and L31V/M/I, R30Q, and/or Y93H/N in HCV genotype 1b, have been detected in patients who experienced virologic failure in clinical trials;1 some of these patients also had baseline NS5A polymorphisms at resistance-associated amino acid positions.1 In clinical trials evaluating ledipasvir/sofosbuvir in patients with HCV genotype 4, 5, or 6 infection, patients with relapse who had NS5A sequencing data available had pretreatment NS5A resistance-associated polymorphisms (single or combinations at positions 24, 28, 30, 31 and 58);1 NS5A resistance-associated substitutions Y93C or L28V emerged posttreatment in a few of the patients with HCV genotype 4 relapse who also had NS5A polymorphisms pretreatment.1

  • Certain amino acid substitutions in NS5B polymerase of HCV genotypes 1b, 4a, 5a, and 6a have been selected in cell culture and have been associated with reduced susceptibility to sofosbuvir in vitro in replicon studies.1 In all replicon genotypes tested, S282T substitution was associated with reduced susceptibility to sofosbuvir;1 in genotypes 5 and 6 replicons, M289L substitution developed along with the S282T substitution.1 Although clinical importance unknown, treatment-emergent NS5B resistance-associated amino acid substitutions (e.g., L159, V321, D61G, A112T, E237G, S473T, S282T, L320V/I, V321I) were detected in clinical trials evaluating ledipasvir/sofosbuvir in patients with HCV genotype 1 infection.1 Treatment-emergent sofosbuvir resistance-associated NS5B substitution S282T reported at time of relapse in patients with HCV genotype 4, 5, or 6 infection who received ledipasvir/sofosbuvir in clinical trials;1 treatment-emergent nucleotide inhibitor substitution M289I also reported in a patient with HCV genotype 5 relapse.1

  • Cross-resistance between ledipasvir and other NS5A inhibitors is expected;1 efficacy of ledipasvir/sofosbuvir not established in patients in whom previous treatment with other regimens that included an NS5A inhibitor failed.1 Ledipasvir and sofosbuvir are both active against HCV with amino acid substitutions associated with resistance to other classes of HCV DAAs that have different mechanisms of action (e.g., HCV NS5B nonnucleoside inhibitors, NS3 protease inhibitors).1

Advice to Patients

  • Advise patients to take ledipasvir/sofosbuvir once daily (with or without food) on a regular dosing schedule.1

  • Inform patients that reactivation of HBV infection has occurred in coinfected patients being treated for HCV infection.1 25 Importance of informing clinician of any history of HBV infection or other liver problems (e.g., cirrhosis).1 25 Importance of immediately contacting a clinician if any signs or symptoms of serious liver injury (e.g., fatigue, weakness, loss of appetite, nausea and vomiting, yellowing of the eyes or skin, light-colored bowel movements) occur.25 (See Risk of HBV Reactivation in Patients Coinfected with HCV and HBV under Cautions.)

  • Importance of taking recommended dosage of ledipasvir/sofosbuvir for the recommended duration of treatment;1 importance of not missing or skipping doses.1

  • If ledipasvir/sofosbuvir is used in a patient receiving amiodarone, advise patient about the risk of serious symptomatic bradycardia and importance of immediately contacting clinician if signs or symptoms of bradycardia (e.g., near-fainting or fainting, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion, memory problems) occur.1 (See Cardiovascular Effects under Cautions.)

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.1

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 If ledipasvir/sofosbuvir is used in conjunction with ribavirin, advise men and women of importance of using effective contraception during and for 6 months after ribavirin therapy.349 (See Precautions Related to Fixed Combinations and Multiple-drug Treatment Regimens under Cautions.)

  • Importance of informing patients of other important precautionary information.1 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Ledipasvir and Sofosbuvir

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Pellets

Ledipasvir 33.75 mg and Sofosbuvir 150 mg

Harvoni

Gilead

Ledipasvir 45 mg and Sofosbuvir 200 mg

Harvoni

Gilead

Tablets, film-coated

Ledipasvir 45 mg and Sofosbuvir 200 mg

Harvoni

Gilead

Ledipasvir 90 mg and Sofosbuvir 400 mg

Harvoni

Gilead

AHFS DI Essentials™. © Copyright 2020, Selected Revisions June 22, 2020. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Gilead Sciences. Harvoni (ledipasvir and sofosbuvir) tablets and oral pellets prescribing information. Foster City, CA; 2020 Mar.

2. Afdhal N, Zeuzem S, Kwo P et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370:1889-98. http://www.ncbi.nlm.nih.gov/pubmed/24725239?dopt=AbstractPlus

3. Kowdley KV, Gordon SC, Reddy KR et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370:1879-88. http://www.ncbi.nlm.nih.gov/pubmed/24720702?dopt=AbstractPlus

4. Afdhal N, Reddy KR, Nelson DR et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370:1483-93. http://www.ncbi.nlm.nih.gov/pubmed/24725238?dopt=AbstractPlus

5. Link JO, Taylor JG, Xu L et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014; 57:2033-46. http://www.ncbi.nlm.nih.gov/pubmed/24320933?dopt=AbstractPlus

6. Gentile I, Buonomo AR, Borgia F et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014; 23:561-71. http://www.ncbi.nlm.nih.gov/pubmed/24593285?dopt=AbstractPlus

7. German P, Moorehead L, Pang P et al. Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects. J Clin Pharmacol. 2014; 54:1290-8. http://www.ncbi.nlm.nih.gov/pubmed/24925712?dopt=AbstractPlus

8. US Food and Drug Administration. Center for Drug Evaluation and Research. Application number 205834Orig1s000. Clinical pharmacology and biopharmaceutics review. From FDA website. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205834Orig1s000ClinPharmR.pdf

9. Bourlière M, Bronowicki JP, de Ledinghen V et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015; 15:397-404. http://www.ncbi.nlm.nih.gov/pubmed/25773757?dopt=AbstractPlus

10. Abergel A, Asselah T, Metivier S et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016; :. http://www.ncbi.nlm.nih.gov/pubmed/26803446?dopt=AbstractPlus

11. Naggie S, Cooper C, Saag M et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373:705-13. http://www.ncbi.nlm.nih.gov/pubmed/26196665?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4892372&blobtype=pdf

12. Efficacy and safety of ledipasvir/sofosbuvir fixed-dose combination in treatment-naive and treatment-experienced subjects with chronic genotype 4 or 5 infection. From ClinicalTrials.gov registry. Accessed 2014 Jun 5 https://clinicaltrials.gov/ct2/show/study/NCT02081079

23. US Food and Drug Administration. FDA drug safety communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Sovaldi in combination with another direct acting antiviral. 2015 Mar 24. From FDA website. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM439492.pdf

25. US Food and Drug Administration. FDA drug safety communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. 2016 Oct 4. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm

26. Britnell SR, Willets AE, Vanderman AJ et al. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Pharmacotherapy. 2016; 36:1173-1179. http://www.ncbi.nlm.nih.gov/pubmed/27716978?dopt=AbstractPlus

27. DeCarolis DD, Westanmo AD, Chen YC et al. Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. Ann Pharmacother. 2016; 50:909-917. http://www.ncbi.nlm.nih.gov/pubmed/27465881?dopt=AbstractPlus

28. Peterson D, Van Ermen A. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin. Am J Health Syst Pharm. 2017; 74:888-892. http://www.ncbi.nlm.nih.gov/pubmed/28596225?dopt=AbstractPlus

29. Schwarz KB, Rosenthal P, Murray KF et al. Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C. Hepatology. 2019; http://www.ncbi.nlm.nih.gov/pubmed/31220349?dopt=AbstractPlus

30. Murray KF, Balistreri WF, Bansal S et al. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Hepatology. 2018; 68:2158-2166. http://www.ncbi.nlm.nih.gov/pubmed/30070726?dopt=AbstractPlus

31. Balistreri WF, Murray KF, Rosenthal P et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017; 66:371-378. http://www.ncbi.nlm.nih.gov/pubmed/27997679?dopt=AbstractPlus

119. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. From the AASLD website. Accessed 2020 Feb 4. http://www.hcvguidelines.org

200. Panel on Antiretroviral Guidelines for Adults and Adolescents, US Department of Health and Human Services (HHS). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Accessed 2020 Apr 20. Updates may be available at HHS AIDS Information (AIDSinfo) website. http://www.aidsinfo.nih.gov

221. Gilead Sciences. Viread (tenofovir disoproxil fumarate) tablets and powder for oral use prescribing information. Foster City, CA; 2019 Apr.

246. Gilead Sciences. Vemlidy (tenofovir alafenamide) tablets prescribing information. Foster City, CA. 2019 Feb.

248. Gilead Sciences. Biktarvy (bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate) tablets prescribing information. Foster City, CA. 2019 Aug.

254. Merck Sharp and Dohme. Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) tablets prescribing information. Whitehouse Station, NJ. 2019 Oct.

349. Merck Sharp & Dohme. Rebetol (ribavirin) capsules and oral solution prescribing information. Whitehouse Station, NJ; 2019 Mar.

Related questions